Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

NCT ID: NCT05698901

Last Updated: 2023-11-18

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-09-19
• Study Completion Date: 2027-09-30

Brief Summary

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene.

It is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The α-Gal A deficiency results in progressive accumulation of un-degraded glycosphingolipids, predominantly globotriaosylceramide (Gb3), within cell lysosomes throughout the body.1

In patients at the fourth to fifth decade, left ventricular hypertrophy occur usually, and myocardial infarction and heart failure develops disease progress. Life-threatening renal, cardiac, and cerebrovascular diseases are added in later decades.2,3

Fabry disease is treatable with enzyme replacement therapy (ERT). Early recognition of symptoms and diagnosis of patients at a potentially reversible stage of the disease is therefore important. To date, plasma Lyso-Gb3 is useful in the diagnosis of Fabry disease. All male with classical Fabry disease could be discerned by an elevated plasma Lyso-GL-3; All adult female patients have elevated plasma Lyso-GL-3 above normal range.4 Other study also indicated that higher lyso-Gb3 concentrations at first visit were associated with a higher event rate in the past. Men with classical FD have higher Lyso-GL-3 values compared with patients with non-classical FD and women along with an increased risk of developing complications, more severe cardiac and renal disease.5

According to a publication from Taiwan society of cariology (TSOC) expert consensus, several cardiac biomarkers including N terminal pro B type natriuretic peptide (NT-proBNP) and cardiac troponin I/T (cTNI/cTNT) have been proposed to be alternative surrogate markers of cardiac involvement in FD.6However, there is no study to analyze the relationship between all these biomarkers including lyso-Gb3 and FD cardiac manifestation or improvement of cardiac damage outcomes under ERT yet.

There is a high prevalence of the cardiac variant (IVS4+919G→A) (~1 in 1600 males) of FD in Taiwan as revealed by newborn screening programs7,8 and patients with idiopathic HCM.9 FD patients with cardiac variant need to fulfill at least two indicators as stated in "cardiac function assessment indicators of Fabry's disease cardiac variant type" with cardiac biopsy confirmed GL3 or lyso-Gb3 lipid accumulation to get local reimbursement for treatment. Cardiac biopsy is an invasive and relative dangerous procedure that some patients would refuse to take this procedure and could not get local reimbursement resulting in delay in treatment.

Therefore in the present study the investigators are aiming to identify candidate biomarkers to establish a scoring algorithm for evaluating Fabry disease progression status or treatment response and the investigators could stage patient who with more correlated biomarkers at baseline would have higher risk to develop sever clinical outcome and initiate early therapy.

Conditions

Fabry Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Group A

1. 18 years or older

2. Male or female with Fabry disease diagnosed

3. Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.

4. ERT Treatment naïve Fabry patients

No interventions assigned to this group

Group B

1. 18 years or older

2. Male or female with Fabry disease diagnosed

3. Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.

4. Agalsidase beta (ERT) exposed or treated Fabry patients

Agalsidase beta

Intervention Type: DRUG

The treatment is following local reimbursement criteria and judge by physician

Interventions

Agalsidase beta

The treatment is following local reimbursement criteria and judge by physician

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 18 years or older
• Male or female with Fabry disease diagnosed
• Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.
• Group A: ERT Treatment naïve Fabry patients
• Group B: Agalsidase beta (ERT) exposed or treated Fabry patients
• Willing and able to comply with the required clinic visits, study procedures and assessments

Exclusion Criteria

• Patient who are unwilling to sign inform consent form

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mackay Memorial Hospital

OTHER

Sponsor Role: lead

Responsible Party

Charles Jia-Yin Hou

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Charles Jia-Yin Hou

Role: STUDY_CHAIR

Mackay Memorial Hospital

Locations

Charles Jia-Yin Hou

Taipei, , Taiwan

Site Status: RECRUITING

Countries

Taiwan

Central Contacts

Charles Jia-Yin Hou

Role: CONTACT

jiayinhou@gmail.com

+886905960500

Facility Contacts

Charles Jia-Yin Hou

Role: primary

jiayinhou@gmail.com

+886905960500

Other Identifiers

22CT026be

Identifier Type: -

Identifier Source: org_study_id